pdufa.bio
Home › Condition › Rare Disease

Upcoming Rare Disease FDA decisions & readouts

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET
PDUFA target dates and trial readouts in rare disease, each linked to its primary source. Updated from FDA/SEC/ClinicalTrials.gov; dates can shift.
Cancer & OncologyObesity & MetabolicCNS & NeurologyImmunology & InflammationCardiovascularInfectious Disease & VaccinesHematologyOphthalmology & Eye

PDUFA decisions (9)

CAPR · 2026-11-22
Deramiocel (CAP-1002) - (HOPE-3): Duchenne muscular dystrophy; refined proposed indication focused on upper limb function
BBIO · 2026-11-27
BBP-418 (ribitol) - (FORTIFY): Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)
DYN · 2027-01-21
Z-rostudirsen - Duchenne muscular dystrophy, exon 51: Duchenne muscular dystrophy amenable to exon 51 skipping
BBIO · 2027-02-04
Oral infigratinib - achondroplasia in children (PROPEL 3): Children with achondroplasia
BMRN · 2027-02-28
VOXZOGO (vosoritide) - full approval, children with achondroplasia: Children with achondroplasia (application for full approval)
PVLA · 2027-02-28
QTORIN rapamycin - microcystic lymphatic malformations (SELVA): Microcystic lymphatic malformations
NTLA · 2027-03-10
Lonvoguran ziclumeran (lonvo-z) - hereditary angioedema: Hereditary angioedema
PHVS · 2027-04-23
Deucrictibant IR - (RAPIDe-3): Hereditary angioedema, on-demand
BMRN · 2027-05-30
VOXZOGO (vosoritide) - hypochondroplasia (sNDA): Hypochondroplasia

Trial readouts (9)

SLDB · Nov 2026 (est.)
SGT-003
CORT · Dec 2026 (est.)
Relacorilant
TSHA · Mar 2027 (est.)
TSHA-101
DYN · 2027-03-31
z-basivarsen ACHIEVE Phase 1/2 Registrational Expansion Cohort (REC): myotonic dystrophy type 1
IONS · Jun 2027 (est.)
Olezarsen
IONS · Aug 2027 (est.)
ION582
CSTL · Sep 2027 (est.)
FCX-007
KRRO · 2027-12-31
KRRO-121 ANCHOR Phase 1/2 Part 2 (UCD patients), INTERIM readout: urea cycle disorders
AKBA · May 2031 (est.)
Vadadustat

Every upcoming FDA decision date, all therapeutic areas, on the 2026 PDUFA calendar · all conditions

We don't show an approval percentage for these rare disease catalysts: here's why.